#USA #Boston #TTX-MC138 #TransCode Therapeutics #RNA cancer therapy

TransCode Therapeutics Secures Financing

In a significant move for the future of cancer treatment, TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced a strategic agreement with an institutional healthcare investor. This new deal provides up to $20 million in flexible financing, enhancing the company's runway into late 2027 or early 2028. TransCode, which specializes in immuno-oncology and RNA technology for advanced cancer therapy, is poised to advance its ambitious projects thanks to this crucial funding.

Key Aspects of the Financing Agreement

The financing structure is notably flexible, which is vital for TransCode as it continues to operate efficiently during pivotal stages of its clinical development. The financial arrangement comprises

• - Pre-paid Advances: An initial amount of up to $6 million will be made available to the company.
• - Standby Equity Purchase Agreement (SEPA): This agreement allows TransCode to sell up to $14 million of its common stock to the investor over the next three years. Such flexibility is essential for ongoing trials and potential collaborations.

The CEO of TransCode, Dr. Philippe P Calais, stated, "This financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, TTX-MC138." This reassurance of funding comes at a crucial time for the company, as it prepares to push forward with the next phases of its clinical studies.

Details of the TTX-MC138 Therapy

TTX-MC138, TransCode’s lead therapeutic candidate, is designed to target microRNA-10b—a molecule believed to play a significant role in the development and spread of various metastatic cancers. The results from the company's initial Phase 0 clinical trial showed promising signs of the therapeutic's effectiveness, indicating successful delivery to metastatic lesions and activity even at low doses. The milestone Phase 1a trial confirmed the drug's safety profile, a critical factor as the company gears up for Phase 2a tests expected to start in the second quarter of 2026.

This innovative approach to targeting metastatic tumors reflects TransCode's commitment to advancing cancer therapies that utilize cutting-edge research in RNA technology and immunotherapy. The management team believes this financing allows them to harness the full potential of TTX-MC138, as they also explore strategic partnerships to enhance the program's reach and efficacy.

Structure and Conditions of the Financing

In terms of structure, the pre-paid advances will be documented with convertibles notes priced at 95% of face value. The company will issue an initial $1 million note in line with its Annual Report for the year ended December 31, 2025. An additional $5 million note will follow, contingent upon shareholder approval, as per Nasdaq regulations. Importantly, the advances come with a manageable 5% simple annual interest and an option for the investor to convert their investment into equity.

The strategic partnership with Tungsten Advisors as the sole placement agent further solidifies the financing's credibility and potential impact on TransCode's future.

Looking Ahead

With these new funds, TransCode is not only looking to complete its ongoing clinical trials but is also exploring broader collaborations that could enhance the development of TTX-MC138 and other treatments in its pipeline. This financing agreement is essential in ensuring that TransCode remains at the forefront of the fight against cancer, focusing on therapies that can make a real difference in patient outcomes.

As they move ahead, the focus will be on delivering results that could redefine cancer treatment paradigms while inspiring confidence among investors and stakeholders alike. Staying abreast of the developments in the immunotherapy landscape will be crucial, especially in light of the dynamic challenges faced in drug discovery and clinical trials. The dedicated resources from this financing will play a pivotal role in navigating these complexities as TransCode Therapeutics pushes forward into new therapeutic territories.